Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16824896 | 0.87 | RXFP1 (0.52) | MAPTLMNAKDM4ERXFP1NPC1 | |
| SCHEMBL16166923 | 0.85 | MAPT (0.70) | MAPTLMNAKDM4ERXFP1NPC1 | |
| SCHEMBL20873927 | 0.85 | MAPT (0.70) | MAPTLMNAKDM4ERXFP1NPC1 | |
| SCHEMBL15206887 | 0.83 | MAPT (0.67) | MAPTLMNAKDM4ERXFP1NPC1 | |
| SCHEMBL16824972 | 0.83 | RXFP1 (0.58) | MAPTLMNAKDM4ERXFP1NPC1 | |
| SCHEMBL16824859 | 0.82 | RXFP1 (0.48) | MAPTLMNAKDM4ERXFP1KMT2A | |
| SCHEMBL30656122 | 0.82 | RXFP1 (0.48) | MAPTLMNAKDM4ERXFP1KMT2A | |
| SCHEMBL28094395 | 0.79 | RXFP1 (0.46) | MAPTLMNAKDM4ERXFP1NPC1 | |
| SCHEMBL14875553 | 0.78 | MAPT (0.45) | MAPTLMNAKDM4ERXFP1NPC1 | |
| SCHEMBL1815515 | 0.77 | MAPT (0.55) | MAPTLMNAKDM4ERXFP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083625-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | Almac Discovery Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| CN-105829315-A | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | 阿尔麦克探索有限公司 | 2016-08-03 | — | — | CN | disclosed |
| WO-2015092431-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | MAPT 3728/4885LMNA 3631/4885KDM4E 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.